Published in J Am Coll Cardiol on October 02, 2002
Matter of Fat: Are Lipids Antiarrhythmic? Circ Arrhythm Electrophysiol (2015) 1.39
Identification of a binding motif in the S5 helix that confers cholesterol sensitivity to the TRPV1 ion channel. J Biol Chem (2011) 1.05
Comparative analysis of cholesterol sensitivity of Kir channels: role of the CD loop. Channels (Austin) (2010) 1.01
Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol (2006) 0.99
Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification. Heart (2004) 0.99
Cholesterol and Kir channels. IUBMB Life (2009) 0.94
Effects of exercise training and hypercholesterolemia on adenosine activation of voltage-dependent K+ channels in coronary arterioles. J Appl Physiol (1985) (2008) 0.88
The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention. Tex Heart Inst J (2011) 0.86
Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury. PLoS One (2015) 0.84
Establishment and characterization of an experimental model of coronary thrombotic microembolism in rats. Am J Pathol (2010) 0.80
Effects of intravenous diltiazem in a rat model of experimental coronary thrombotic microembolism. Exp Ther Med (2013) 0.77
Cholesterol down-regulates BK channels stably expressed in HEK 293 cells. PLoS One (2013) 0.76
Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats. Exp Ther Med (2015) 0.75
Ischemic preconditioning: Interruption of various disorders. J Saudi Heart Assoc (2016) 0.75
No-Reflow Phoenomenon by Intracoronary Thrombus in Acute Myocardial Infarction. Chonnam Med J (2016) 0.75
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet (2009) 3.67
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem (2006) 3.18
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: The Tanno and Sobetsu study. Diabetes Care (2006) 2.15
Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens (2004) 1.81
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest (2014) 1.77
Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med (2008) 1.74
Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol (2007) 1.70
Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb (2007) 1.70
Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem (2010) 1.65
Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med (2010) 1.64
Noninvasive assessment of left atrial function by strain rate imaging in patients with hypertension: a possible beneficial effect of renin-angiotensin system inhibition on left atrial function. Hypertens Res (2007) 1.64
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension (2003) 1.62
Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res (2006) 1.57
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol (2005) 1.46
Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb (2007) 1.45
microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol (2011) 1.45
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res (2008) 1.44
Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev (2013) 1.44
Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle. Hypertens Res (2005) 1.43
GSK-3beta, a therapeutic target for cardiomyocyte protection. Circ J (2009) 1.42
Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension--a legacy effect? Hypertens Res (2011) 1.39
Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett (2004) 1.38
Strain rate imaging for noninvasive functional quantification of the left atrium: comparative studies in controls and patients with atrial fibrillation. J Am Soc Echocardiogr (2005) 1.35
Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res (2004) 1.33
Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet (2011) 1.32
Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol (2008) 1.31
Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol (2012) 1.21
Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury. Circ Res (2010) 1.20
Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol (2006) 1.19
Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care (2003) 1.18
Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One (2011) 1.13
Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men--the Tanno and Sobetsu Study. Hypertens Res (2005) 1.11
Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning. Am J Physiol Heart Circ Physiol (2002) 1.10
Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J Pharmacol Exp Ther (2011) 1.10
Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol (2006) 1.08
Relationship between visceral fat and cardiovascular disease risk factors: the Tanno and Sobetsu study. Hypertens Res (2007) 1.08
Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol (2012) 1.08
Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens (2012) 1.06
Metabolic syndrome. J Atheroscler Thromb (2008) 1.06
Left ventricular hypertrophy causes different changes in longitudinal, radial, and circumferential mechanics in patients with hypertension: a two-dimensional speckle tracking study. J Am Soc Echocardiogr (2010) 1.06
Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology (2003) 1.05
Lipid chaperones and metabolic inflammation. Int J Inflam (2011) 1.03
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res (2008) 1.03
Effect of intravenous propranolol on left ventricular apical ballooning without coronary artery stenosis (ampulla cardiomyopathy): three cases. Circ J (2002) 1.03
Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol (2008) 1.03
Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium. Intern Med (2011) 1.02
Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One (2013) 1.01
ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol (2003) 1.00
Quantitative assessment of left ventricular and left atrial functions by strain rate imaging in diabetic patients with and without hypertension. Echocardiography (2008) 0.99
Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol Heart Circ Physiol (2003) 0.99
Insulin sensitivity and lipid metabolism in human CD36 deficiency. Diabetes Care (2003) 0.99
Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial (2012) 0.99
Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. Cardiovasc Pathol (2005) 0.98
The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res (2005) 0.98
Liddle's syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel beta-subunit. J Clin Endocrinol Metab (2004) 0.98
Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling. Circ Res (2014) 0.98
Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res (2012) 0.98
Assessment of left ventricular ejection fraction using long-axis systolic function is independent of image quality: a study of tissue Doppler imaging and m-mode echocardiography. Echocardiography (2006) 0.98
Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J (2004) 0.97
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury. J Pharmacol Sci (2009) 0.97
Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertens Res (2012) 0.96
Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem (2013) 0.95